FIGURE 6.
Flow cytometry for intracellular TRAIL on cultured PBMC (A), influence of treatment (zoledronate ± IL-2) on serum TRAIL concentrations (B), and association between TRAIL concentrations and clinical outcome (C). A, percentage of Vγ9+CD3+ cells positive for TRAIL on day 3 (n = 5 healthy volunteers). Points, mean; bars, SE. B, TRAIL concentration in serum of patients treated with zoledronate only or zoledronate + IL-2, analyzed at indicated time points. See the legend to Fig. 2. C, TRAIL concentrations assessed at 9 mo after therapy are shown for three patients with partial remission, five patients with stable disease, and three patients with progression. Lines, median values.